R&D
Page 1 • 3 itemsGain critical insights into global pharmaceutical R&D trends, drug discovery pipelines, and clinical trial advancements. Drive your pharma strategy.
GHIT Fund Invests $8.5 Million in Malaria and NTD Drug Development with GSK, Eisai Partners
GHIT Fund announces $8.5 million investment across five R&D projects for malaria and neglected tropical disease treatments with major pharma partners.
NMPA Grants Breakthrough Therapy Designation to Innovent's KRAS G12C Inhibitor
The NMPA has granted breakthrough therapy designation to Innovent's KRAS G12C inhibitor, marking a significant advancement in the treatment of advanced solid tumors.
PMDA Accepts Shionogi Novel Influenza Drug with SAKIGAKE Designation
The PMDA has accepted Shionogi's novel influenza drug, recognized with SAKIGAKE designation, marking a significant advancement in flu treatment.